Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
54
OCGN Quote, Financials, Valuation and Earnings
Last price:
$1.79
Seasonality move
:
5.38%
Day range:
$1.79 - $1.90
52-week range:
$0.57 - $2.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
120.38x
P/B ratio:
181.62x
Volume:
7.3M
Avg. volume:
11M
1-year change:
176.58%
Market cap:
$580.5M
Revenue:
$4.4M
EPS (TTM):
-$0.23
Analysts' Opinion
-
Consensus RatingOcugen, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.57, Ocugen, Inc. has an estimated upside of 546.45% from its current price of $1.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing -291.06% downside risk from its current price of $1.79.
Fair Value
-
According to the consensus of 6 analysts, Ocugen, Inc. has 546.45% upside to fair value with a price target of $11.57 per share.
OCGN vs. S&P 500
-
Over the past 5 trading days, Ocugen, Inc. has underperformed the S&P 500 by -11.09% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ocugen, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ocugen, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ocugen, Inc. reported revenues of -$193K.
Earnings Growth
-
Ocugen, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Ocugen, Inc. reported earnings per share of -$0.06.
Enterprise value:
601.5M
EV / Invested capital:
--
Price / LTM sales:
120.38x
EV / EBIT:
--
EV / Revenue:
136.30x
PEG ratio (5yr expected):
-0.61x
EV / Free cash flow:
-10.53x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.8M
Return On Assets:
-111.85%
Net Income Margin (TTM):
-1537.41%
Return On Equity:
-848.82%
Return On Invested Capital:
-166.93%
Operating Margin:
-1005.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $6M | $4.1M | $4.4M | $764K | -$193K | |
| Gross Profit | $5.3M | $2.1M | $1.8M | $166K | -- | |
| Operating Income | -$65.5M | -$54.8M | -$62.9M | -$13.8M | -$17M | |
| EBITDA | -$64.8M | -$52.8M | -$60.5M | -$13.2M | -$17.4M | |
| Diluted EPS | -$0.26 | -$0.20 | -$0.23 | -$0.05 | -$0.06 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $102.6M | $98.5M | $43M | $61.7M | $24.3M | |
| Total Assets | $105.8M | $109.6M | $65.5M | $83.3M | $44.3M | |
| Current Liabilities | $7M | $28.5M | $17.1M | $21.6M | $23M | |
| Total Liabilities | $9.9M | $35.6M | $24.9M | $53.7M | $56.5M | |
| Total Equity | $95.8M | $74M | $40.6M | $29.6M | -$12.2M | |
| Total Debt | $2.9M | $5.9M | $6.4M | $32M | $32.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62.1M | -$42.1M | -$57M | -$10.4M | -$14M | |
| Cash From Investing | $3.1M | -$3.4M | -$311K | -$13K | -$35K | |
| Cash From Financing | $20.9M | $64.9M | $17.3M | $30.2M | $2K | |
| Free Cash Flow | -$72.5M | -$45.5M | -$57.1M | -$10.4M | -$14M | |
OCGN
Sector
Market Cap
$580.5M
$24.3M
Price % of 52-Week High
65.69%
46.97%
Dividend Yield
0%
0%
Shareholder Yield
-5.6%
-1.86%
1-Year Price Total Return
176.58%
-17.65%
Beta (5-Year)
2.803
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.89
200-day SMA
Buy
Level
$1.40
Bollinger Bands (100)
Buy
Level
1.24 - 1.88
Chaikin Money Flow
Sell
Level
-53.8M
20-day SMA
Sell
Level
$2.02
Relative Strength Index (RSI14)
Sell
Level
44.96
ADX Line
Sell
Level
45.2
Williams %R
Buy
Level
-93.9698
50-day SMA
Buy
Level
$1.76
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Sell
Level
-41.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.9704)
Sell
CA Score
(Annual)
Level (-6.5505)
Buy
Beneish M-Score
(Annual)
Level (-4.3099)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (11.1585)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Stock Forecast FAQ
In the current month, OCGN has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OCGN average analyst price target in the past 3 months is $11.57.
-
Where Will Ocugen, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ocugen, Inc. share price will rise to $11.57 per share over the next 12 months.
-
What Do Analysts Say About Ocugen, Inc.?
Analysts are divided on their view about Ocugen, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ocugen, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Ocugen, Inc.'s Price Target?
The price target for Ocugen, Inc. over the next 1-year time period is forecast to be $11.57 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OCGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ocugen, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OCGN?
You can purchase shares of Ocugen, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ocugen, Inc. shares.
-
What Is The Ocugen, Inc. Share Price Today?
Ocugen, Inc. was last trading at $1.79 per share. This represents the most recent stock quote for Ocugen, Inc.. Yesterday, Ocugen, Inc. closed at $1.79 per share.
-
How To Buy Ocugen, Inc. Stock Online?
In order to purchase Ocugen, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get OCGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
OCGN
Sector
P/E ratio
--
21.48x
PEG ratio
-0.61x
-0.01x
P/B ratio
181.62x
1.72x
Price / LTM sales
120.38x
1.44x
Growth Metrics
OCGN
Sector
Revenue growth
-125.26%
3.36%
Earnings growth
-18.87%
14.79%
Revenue (5-year growth)
152.94%
6.26%
Earnings forecast
-$0.05
-$0.22
Profitability
OCGN
Sector
Profitability FY 2025
$2M
$2.4M
Return on invested capital
-166.93%
-33.32%
Return on assets
-111.85%
-29.45%
Return on equity
-848.82%
-40.29%
Earnings Date
Last Earnings Date
Mar
4
Next Earnings Date
May
7
Estimated Next Earnings Date
Jun
3
Balance Sheet
OCGN
Sector
Total cash
$18.6M
$25.7M
Short term investments
--
$22.7M
Total assets
$44.3M
$70.4M
Long term debt
$32.3M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
27
RH alert for Apr 2
RH [RH] is up 0.2% over the past day.
Sell
43
AXTI alert for Apr 2
AXT, Inc. [AXTI] is up 9.82% over the past day.
Buy
72
CAR alert for Apr 2
Avis Budget Group, Inc. [CAR] is up 10.65% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
